| domain | established finding | evidence type | key identifier/statistic | evidence limitation |
|---|---|---|---|---|
| Definition / phenotype | Craniometaphyseal dysplasia (CMD) is a very rare genetic craniotubular skeletal disorder with progressive craniofacial hyperostosis and flared/widened metaphyses of long bones; major morbidity comes from cranial foraminal narrowing causing facial palsy, hearing loss, blindness, headache, and characteristic facial features such as hypertelorism and prominent mandible. (pqac-00000007, pqac-00000008, pqac-00000009, pqac-00000014) | Human clinical descriptions; observational registry/trial record; review/preclinical introductions | MONDO_0015465; OMIM/MIM #123000; can be diagnosed in infancy; symptoms progress throughout life. (pqac-00000007, pqac-00000012, pqac-00000014) | No robust population-based natural history series or phenotype frequency estimates were available in the retrieved evidence. |
| ANKH autosomal dominant disease | Autosomal dominant CMD is caused by heterozygous ANKH mutations, often in the C-terminal/cytoplasmic region; recurrent/representative mutations include in-frame deletions such as Phe377del and Ser375del, and de novo cases occur. (pqac-00000007, pqac-00000009, pqac-00000010, pqac-00000014) | Human molecular genetics; segregation/case reports; functional cell studies; mouse knock-in support | PMID 11326338 cited in trial record; common mutation noted: phenylalanine 377 deletion; Open Targets links ANKH to CMD. (pqac-00000004, pqac-00000007, pqac-00000008) | Detailed variant spectrum, ACMG classifications, and population allele frequencies were not fully enumerated in retrieved sources. |
| GJA1 autosomal recessive disease | Autosomal recessive CMD is linked to a homozygous GJA1 missense variant c.716G>A (p.Arg239Gln), confirmed across multiple families and absent from unaffected relatives except as heterozygotes. (pqac-00000011, pqac-00000012, pqac-00000014) | Human exome sequencing and familial segregation | PMID 23951358; 6 affected individuals from 3 additional families; exome depth ~78x in proband; variant novel vs dbSNP/HGMD/1000 Genomes/ESP at publication. (pqac-00000011, pqac-00000012, pqac-00000004) | Evidence is based on a small number of families; disrupted remodeling mechanism for this Cx43 mutation remained unresolved in the primary paper. |
| Core mechanism | ANK/ANKH regulates extracellular mineralization by exporting ATP and PPi (and more recently recognized citrate/ATP-related small molecules); reduced extracellular PPi favors excess hydroxyapatite deposition. CMD-linked ANK/ANKH mutants show reduced steady-state protein, rapid degradation, and cytoplasmic mislocalization, with downstream osteoblast/osteoclast dysfunction. (pqac-00000008, pqac-00000009, pqac-00000010, pqac-00000014) | Human and mouse cell biology; mouse genetics; mechanistic review/preprint | Mutant ANK/ANKH is “short-lived and mislocalized”; ANK localizes to plasma membrane, ER, Golgi, lysosomes when wild type. (pqac-00000009, pqac-00000010, pqac-00000014) | Exact contribution of loss-of-function versus novel dominant effects remains unresolved; some mechanistic claims rely on mouse/cell systems rather than direct patient tissues. |
| Diagnosis | Best-supported diagnosis is clinical plus radiographic plus molecular genetics: lifelong craniofacial hyperostosis with metaphyseal flaring and characteristic craniofacial features, confirmed by sequencing of ANKH and, if recessive pattern/no ANKH variant, GJA1. (pqac-00000007, pqac-00000012, pqac-00000014, pqac-00000022) | Observational trial record; human genetics papers; current disease review | Estimated observational study enrollment 600 in ongoing UConn protocol NCT01630460. (pqac-00000007) | Retrieved evidence did not provide formal consensus diagnostic criteria, test sensitivity/specificity, or a comprehensive differential diagnosis algorithm specific to CMD. |
| Treatment | There is no established curative medical therapy; care is largely supportive and surgical, including decompression of obstructed foramina and craniofacial contouring/reconstructive procedures, often repeated for symptom relief. Historical calcitriol/calcitonin use is cited in literature but robust modern efficacy data were not retrieved. (pqac-00000009, pqac-00000014) | Human case-management summaries; review statements; historical literature references noted | Current treatment described as limited to surgical decompression/plastic surgery or repetitive surgical recontouring. (pqac-00000008, pqac-00000009, pqac-00000014) | Evidence base is dominated by case reports/older reports; no approved disease-modifying drug or controlled therapeutic trials for CMD were identified. |
| 2024 ENPP1 mouse experiment | In AnkKI/KI mice, weekly subcutaneous IMA2a from age 1 week for 12 weeks restored plasma PPi and reduced ectopic calcification but did not rescue core CMD skeletal abnormalities (skull hyperostosis, mandible overgrowth, widened metaphyses, narrowed foramen magnum). (pqac-00000013, pqac-00000014, pqac-00000023, pqac-00000024) | Peer-reviewed 2024 mouse interventional study | n≥6/group; ENPP1 activity 28.15 ± 1.65 vs 482.7 ± 331.2 mOD/min; plasma PPi 0.94 ± 0.5 (WT) / 0.43 ± 0.2 (KI vehicle) / 1.29 ± 0.8 μM (KI IMA2a); visible skull calcification in 8/12 KI vehicle vs 7/12 KI IMA2a mice. (pqac-00000013, pqac-00000014) | Preclinical mouse data only; benefit was limited to ectopic calcification under the tested regimen and does not establish clinical efficacy in humans. |
| Models | CMD research is supported by Ank knock-in mice (Phe377del) that closely phenocopy human disease, Ank knockout mice that reproduce partial features, human iPSC-derived osteoclast differentiation studies, and emerging zebrafish ankh paralog work for developmental and screening applications. (pqac-00000007, pqac-00000008, pqac-00000009, pqac-00000014) | Mouse, iPSC, zebrafish, clinical observational study | AnkKI/KI replicates thick skull, narrowed foramen magnum, fused middle ear bones, obliterated nasal sinuses, stenotic cranial foramina, metaphyseal widening, mandibular hyperostosis; zebrafish show craniofacial/notochord/somite expression of ankha/ankhb. (pqac-00000008, pqac-00000009) | Mouse inheritance/expressivity do not perfectly mirror human AD disease; zebrafish 2024 evidence is preprint and functional roles remain speculative. |


*Table: This table condenses the most decision-relevant evidence for craniometaphyseal dysplasia across disease definition, genetics, mechanism, diagnosis, treatment, and models. It is useful as a quick reference for knowledge-base curation while highlighting where evidence remains sparse or preclinical.*